Table 2 Methylation status of SOCS3 promoter fragments
From: Prediction of steroid resistance and steroid dependence in nephrotic syndrome children
SOCS3 promoter fragment | Study Group | MMb n (%) | MUc n (%) | UUd n (%) | OR [95% CI] | P-value |
|---|---|---|---|---|---|---|
SOCS3_1 | NS patients n = 124 | 3 (2%) | 115 (93%) | 6 (5%) | NS vs. C: 2.8 [0.3–23.4] | 0.3552 |
(− 1070/− 926 bp) a | SR patients n = 53 | 0 (0%) | 51 (96%) | 2 (4%) | SR vs.SS: 0.7 [0.1–3.7] | 0.6351 |
SS patients n = 71 | 3 (4%) | 64 (90%) | 4 (6%) | SR vs.SD: 0.6 [0.1–4.3] | 0.5824 | |
PSS patients n = 40 | 1 (2%) | 37 (93%) | 2 (5%) | SR vs.PSS: 0.8 [0.1–5.5] | 0.7736 | |
SD patients n = 31 | 2 (6,5%) | 27 (87%) | 2 (6,5%) | SD vs.PSS: 1.3 [0.2–9.9] | 0.793 | |
Controls n = 55 | 1 (2%) | 53 (96%) | 1 (2%) | SS vs. C: 3.2 [0.4–29.7] | 0.3015 | |
SOCS3_2 | NS patients n = 124 | 0 (0%) | 84 (68%) | 40 (32%) | NS vs. C: 6.1 [2.1–18] | 0.0011** |
(− 256/− 285 bp) | SR patients n = 53 | 0 (0%) | 20 (38%) | 33 (62%) | SR vs.SS: 15.1 [5.8–39.3] | < 0.0001*** |
SS patients n = 71 | 0 (0%) | 64 (90%) | 7 (10%) | SR vs.SD: 15.4 [5.1–57.3] | < 0.0001*** | |
PSS patients n = 40 | 0 (0%) | 36 (90%) | 4 (10%) | SR vs.PSS: 14.9 [4.6–48] | < 0.0001*** | |
SD patients n = 31 | 0 (0%) | 28 (90.3%) | 3 (9.7%) | SD vs.PSS: 1 [0.2–4.7] | 0.9639 | |
Controls n = 55 | 0 (0%) | 51 (92.7%) | 4 (7.3%) | SS vs. C: 1.4 [0.4–5] | 0.6113 |